U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H16N4O4
Molecular Weight 268.2696
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENTOSTATIN

SMILES

C1[C@@]([H])([C@@]([H])(CO)O[C@@]1([H])n2cnc3[C@@]([H])(CN=CNc32)O)O

InChI

InChIKey=FPVKHBSQESCIEP-JQCXWYLXSA-N
InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including https://livertox.nih.gov/Pentostatin.htm

Pentostatin, also known as 2’-deoxycoformycin (DCF) under the trade name Nipent, is a potent inhibitor of the enzyme adenosine deaminase and is isolated from fermentation cultures of Streptomyces antibioticus. It was developed by Parke-Davis (now Pfizer) and the National Cancer Institute in the US. Nipent is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Pentostatin is a potent transition state inhibitor of the enzyme adenosine deaminase (ADA). The greatest activity of ADA is found in cells of the lymphoid system with T-cells having higher activity than B-cells, and T-cell malignancies having higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA, particularly in the presence of adenosine or deoxyadenosine, leads to cytotoxicity, and this is believed to be due to elevated intracellular levels of dATP, which can block DNA synthesis through inhibition of ribonucleotide reductase. Pentostatin can also inhibit RNA synthesis as well as cause increased DNA damage. In addition to elevated dATP, these mechanisms may also contribute to the overall cytotoxic effect of pentostatin. The precise mechanism of pentostatin’s antitumor effect, however, in hairy cell leukemia is not known. In several instances, hepatic toxicity from pentostatin appeared to be somewhat dose related, suggesting that the liver injury is a direct effect of the purine analogue. Because pentostatin is a potent immunosuppressive agent, the possibility exists that some cases of hepatic injury are due to reactivation of hepatitis B or other opportunistic infections. While pentostatin has not been shown to cause reactivation of hepatitis B, there is a strong possibility that it might induce this syndrome, and several cases of hepatic injury during pentostatin therapy were described as due to concurrent hepatitis B.

Originator

Curator's Comment:: # Parke-Davis (now Pfizer) and the National Cancer Institute in the US

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NIPENT

Approved Use

NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.

Launch Date

6.8713919E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
102.2 μg/L
1.5 mg/m² 1 times / day multiple, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PENTOSTATIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
363.3 μg × h/L
1.5 mg/m² 1 times / day multiple, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
PENTOSTATIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.7 h
4 mg/m² single, intravenous
dose: 4 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENTOSTATIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg/m2 1 times / day multiple, intravenous
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 60 years (range: 44-74 years)
n = 29
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukaemia
Age Group: 60 years (range: 44-74 years)
Sex: M+F
Population Size: 29
Sources:
Other AEs: Anaemia, Neutropenia...
Other AEs:
Anaemia (grade 3-4, 1%)
Neutropenia (grade 3-4, 5%)
Thrombocytopenia (grade 3-4, 3%)
Hepatic and hepatobiliary disorders NEC (grade 4, 1%)
Alopecia (grade 1, 2%)
Nausea and vomiting (grade 2-3, 12%)
Diarrhoea (grade 1-2, 4%)
Rash (grade 1-2, 2%)
Conjunctivitis (grade 1-2, 3%)
Infection (grade 2-4, 9%)
Sources:
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Other AEs: Granulocytopenia, Emesis...
Other AEs:
Granulocytopenia (all grades, 36%)
Emesis (all grades, 21%)
Fever (all grades, 26%)
Renal insufficiency (all grades, 19%)
Thrombocytopenia (all grades, 21%)
Diarrhea (all grades, 7%)
Fatigue (all grades, 17%)
Fungal infection (all grades, 12%)
Systemic herpes zoster infection (all grades, 12%)
Infection (all grades, 24%)
Pancreatitis (all grades, 7%)
Bronchospasm (all grades, 2%)
Sources:
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Other AEs: Osteomyelitis, Nausea and vomiting...
Other AEs:
Osteomyelitis (1%)
Nausea and vomiting (63%)
Fever (46%)
Rash (43%)
Fatigue (42%)
Leukopenia (22%)
Pruritus (21%)
Cough increased (20%)
Myalgia (19%)
Chills (19%)
Headache (17%)
Diarrhea (17%)
Abdominal pain (16%)
Anorexia (13%)
Asthenia (12%)
Stomatitis (12%)
Dyspnea (11%)
Anemia (8%)
Pain (8%)
Pharyngitis (8%)
Sweating increased (8%)
Viral infection (8%)
Arthralgia (6%)
Thrombocytopenia (6%)
Skin disorder (4%)
Allergic reaction (2%)
Hepatic function disorder (2%)
Neurologic disorder NOS (1%)
Upper respiratory infection (13%)
Rhinitis (11%)
Herpes zoster (8%)
Pharyngitis (8%)
Viral infection (8%)
Infection NOS (7%)
Sinusitis (6%)
Cellulitis (6%)
Bacterial infection (5%)
Pneumonia (5%)
Conjunctivitis (4%)
Furunculosis (4%)
Herpes simplex (4%)
Bronchitis (3%)
Sepsis (3%)
Urinary tract infection (3%)
Abscesses of skin (2%)
Moniliasis oral (2%)
Infection mycotic (<1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Alopecia grade 1, 2%
2 mg/m2 1 times / day multiple, intravenous
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 60 years (range: 44-74 years)
n = 29
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukaemia
Age Group: 60 years (range: 44-74 years)
Sex: M+F
Population Size: 29
Sources:
Rash grade 1-2, 2%
2 mg/m2 1 times / day multiple, intravenous
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 60 years (range: 44-74 years)
n = 29
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukaemia
Age Group: 60 years (range: 44-74 years)
Sex: M+F
Population Size: 29
Sources:
Conjunctivitis grade 1-2, 3%
2 mg/m2 1 times / day multiple, intravenous
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 60 years (range: 44-74 years)
n = 29
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukaemia
Age Group: 60 years (range: 44-74 years)
Sex: M+F
Population Size: 29
Sources:
Diarrhoea grade 1-2, 4%
2 mg/m2 1 times / day multiple, intravenous
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 60 years (range: 44-74 years)
n = 29
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukaemia
Age Group: 60 years (range: 44-74 years)
Sex: M+F
Population Size: 29
Sources:
Nausea and vomiting grade 2-3, 12%
2 mg/m2 1 times / day multiple, intravenous
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 60 years (range: 44-74 years)
n = 29
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukaemia
Age Group: 60 years (range: 44-74 years)
Sex: M+F
Population Size: 29
Sources:
Infection grade 2-4, 9%
2 mg/m2 1 times / day multiple, intravenous
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 60 years (range: 44-74 years)
n = 29
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukaemia
Age Group: 60 years (range: 44-74 years)
Sex: M+F
Population Size: 29
Sources:
Anaemia grade 3-4, 1%
2 mg/m2 1 times / day multiple, intravenous
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 60 years (range: 44-74 years)
n = 29
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukaemia
Age Group: 60 years (range: 44-74 years)
Sex: M+F
Population Size: 29
Sources:
Thrombocytopenia grade 3-4, 3%
2 mg/m2 1 times / day multiple, intravenous
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 60 years (range: 44-74 years)
n = 29
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukaemia
Age Group: 60 years (range: 44-74 years)
Sex: M+F
Population Size: 29
Sources:
Neutropenia grade 3-4, 5%
2 mg/m2 1 times / day multiple, intravenous
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 60 years (range: 44-74 years)
n = 29
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukaemia
Age Group: 60 years (range: 44-74 years)
Sex: M+F
Population Size: 29
Sources:
Hepatic and hepatobiliary disorders NEC grade 4, 1%
2 mg/m2 1 times / day multiple, intravenous
Dose: 2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / day
Sources:
unhealthy, 60 years (range: 44-74 years)
n = 29
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukaemia
Age Group: 60 years (range: 44-74 years)
Sex: M+F
Population Size: 29
Sources:
Fungal infection all grades, 12%
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Systemic herpes zoster infection all grades, 12%
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Fatigue all grades, 17%
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Renal insufficiency all grades, 19%
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Bronchospasm all grades, 2%
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Emesis all grades, 21%
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Thrombocytopenia all grades, 21%
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Infection all grades, 24%
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Fever all grades, 26%
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Granulocytopenia all grades, 36%
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Diarrhea all grades, 7%
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Pancreatitis all grades, 7%
3.75 mg/m2 1 times / day multiple, intravenous (median)
Dose: 3.75 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.75 mg/m2, 1 times / day
Sources:
unhealthy, 62 years (range: 38-86 years)
n = 42
Health Status: unhealthy
Condition: T-cell lymphoid malignancies
Age Group: 62 years (range: 38-86 years)
Population Size: 42
Sources:
Neurologic disorder NOS 1%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Osteomyelitis 1%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Dyspnea 11%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Rhinitis 11%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Asthenia 12%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Stomatitis 12%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Anorexia 13%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Upper respiratory infection 13%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Abdominal pain 16%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Diarrhea 17%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Headache 17%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Chills 19%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Myalgia 19%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Abscesses of skin 2%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Allergic reaction 2%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Hepatic function disorder 2%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Moniliasis oral 2%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Cough increased 20%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Pruritus 21%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Leukopenia 22%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Bronchitis 3%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Sepsis 3%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Urinary tract infection 3%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Conjunctivitis 4%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Furunculosis 4%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Herpes simplex 4%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Skin disorder 4%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Fatigue 42%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Rash 43%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Fever 46%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Bacterial infection 5%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Pneumonia 5%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Arthralgia 6%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Cellulitis 6%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Sinusitis 6%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Thrombocytopenia 6%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Nausea and vomiting 63%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Infection NOS 7%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Anemia 8%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Herpes zoster 8%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Pain 8%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Pharyngitis 8%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Pharyngitis 8%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Sweating increased 8%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Viral infection 8%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Viral infection 8%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Infection mycotic <1%
4 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 4 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, adult
n = 180
Health Status: unhealthy
Condition: hairy cell leukemia
Age Group: adult
Population Size: 180
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors.
1977 Mar 1
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
1993 Sep
Enhancement by 2'-deoxycoformycin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of 2',3'-dideoxyadenosine and 2'-beta-fluoro-2',3'-dideoxyadenosine.
1994 Nov
Antifungal activity of 3'-deoxyadenosine (cordycepin).
1998 Jun
[Levetiracetam hepatitis].
2004 Jan 17
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
2007 Jan 15
Investigations into the origin of the molecular recognition of several adenosine deaminase inhibitors.
2011 Jan 13
Patents

Sample Use Guides

The recommended dosage of NIPENT (pentostatin for injection) for the treatment of hairy cell leukemia is 4 mg/m2 every other week. NIPENT may be administered intravenously by bolus injection or diluted in a larger volume and given over 20 to 30 minutes.
Route of Administration: Intravenous
It was examined the cytotoxic effects of the purine analogue 2'-deoxycoformycin (Pentostatin, dCF) on cultured mononuclear cells and purified gammadelta+ tumour cells from bone marrow or peripheral blood of four patients with hepatosplenic gammadelta+ T-cell lymphoma. At a concentration of 10 microM, dCF, in the presence of 2'-deoxyadenosine (dAdo), displayed an early and selective cytotoxic effect on gammadelta+ tumour T cells. After 48 h of in vitro exposure to dCF, the absolute number of viable CD3+/gammadelta+ tumour T cells was reduced by more than 90% in all samples with respect to control cultures, with absolute counts of viable CD3+/alphabeta+ lymphocytes being reduced only by 6-40% of the initial cell input..
Name Type Language
PENTOSTATIN
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
PENTOSTATIN [VANDF]
Common Name English
IMIDAZO(4,5-D)(1,3)DIAZEPIN-8-OL, 3-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-3,6,7,8-TETRAHYDRO-, (R)-
Common Name English
PENTOSTATIN [HSDB]
Common Name English
(R)-3-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-3,6,7,8-TETRAHYDROIMIDAZO(4,5-D)(1,3)DIAZEPIN-8-OL
Common Name English
PENTOSTATIN [JAN]
Common Name English
NIPENT
Brand Name English
PENTOSTATIN [ORANGE BOOK]
Common Name English
YK-176
Code English
PENTOSTATIN [MART.]
Common Name English
PENTOSTATIN [MI]
Common Name English
DEOXYCOFORMYCIN
Common Name English
NSC-218321
Code English
PD 81565
Code English
PENTOSTATIN [WHO-DD]
Common Name English
CI-825
Code English
PENTOSTATIN [INN]
Common Name English
PENTOSTATIN [USAN]
Common Name English
PD-81565
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 123899
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
FDA ORPHAN DRUG 50390
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
NDF-RT N0000175595
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
NDF-RT N0000000233
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
LIVERTOX 759
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
FDA ORPHAN DRUG 111998
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
WHO-VATC QL01XX08
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
WHO-ATC L01XX08
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
NCI_THESAURUS C2157
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
FDA ORPHAN DRUG 21287
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
Code System Code Type Description
IUPHAR
4805
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
INN
4355
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
WIKIPEDIA
PENTOSTATIN
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
FDA UNII
395575MZO7
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
DRUG BANK
DB00552
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
MERCK INDEX
M8518
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY Merck Index
PUBCHEM
439693
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
DRUG CENTRAL
2098
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
ChEMBL
CHEMBL1580
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
MESH
D015649
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
EPA CompTox
53910-25-1
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
CAS
53910-25-1
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
EVMPD
SUB09704MIG
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
RXCUI
8011
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY RxNorm
HSDB
6547
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY
NCI_THESAURUS
C732
Created by admin on Sat Jun 26 13:18:27 UTC 2021 , Edited by admin on Sat Jun 26 13:18:27 UTC 2021
PRIMARY